Your browser doesn't support javascript.
loading
Modelling liver cancer initiation with organoids derived from directly reprogrammed human hepatocytes.
Sun, Lulu; Wang, Yuqing; Cen, Jin; Ma, Xiaolong; Cui, Lei; Qiu, Zhixin; Zhang, Zhengtao; Li, Hong; Yang, Run-Zhou; Wang, Chenhua; Chen, Xiaotao; Wang, Le; Ye, Yao; Zhang, Haibin; Pan, Guoyu; Kang, Jian-Sheng; Ji, Yuan; Zheng, Yun-Wen; Zheng, Shan; Hui, Lijian.
Afiliação
  • Sun L; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Wang Y; Department of Pediatric Surgery, Children's Hospital of Fudan University, Shanghai, China.
  • Cen J; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Ma X; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Cui L; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Qiu Z; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Zhang Z; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Li H; Key Lab of Computational Biology, CAS-MPG Partner Institute for Computational Biology, Shanghai Institutes for Biological Sciences, Chinese Academy of Sciences, Shanghai, China.
  • Yang RZ; Shanghai Institute for Nutrition and Health, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Wang C; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Chen X; State Key Laboratory of Cell Biology, Chinese Academy of Sciences Center for Excellence in Molecular Cell Science, Shanghai Institute of Biochemistry and Cell Biology, Chinese Academy of Sciences, University of Chinese Academy of Sciences, Shanghai, China.
  • Wang L; Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Ye Y; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China.
  • Zhang H; Fifth Department of Hepatic Surgery, Eastern Hepatobiliary Surgery Hospital, Second Military Medical University, Shanghai, China.
  • Pan G; Center for Drug Safety Evaluation and Research, Shanghai Institute of Materia Medica, Chinese Academy of Sciences, Shanghai, China.
  • Kang JS; The First Affiliated Hospital of Zhengzhou University, Zhengzhou, China.
  • Ji Y; Department of Pathology, Zhongshan Hospital, Fudan University, Shanghai, China. ji.yuan@zs-hospital.sh.cn.
  • Zheng YW; Faculty of Medicine, University of Tsukuba, Tsukuba-shi, Japan. ywzheng@md.tsukuba.ac.jp.
  • Zheng S; School of Medicine, Yokohama City University, Yokohama, Japan. ywzheng@md.tsukuba.ac.jp.
  • Hui L; Institute of Regenerative Medicine, Jiangsu University, Zhenjiang, China. ywzheng@md.tsukuba.ac.jp.
Nat Cell Biol ; 21(8): 1015-1026, 2019 08.
Article em En | MEDLINE | ID: mdl-31332348
Human liver cancers, including hepatocellular carcinomas and intra-hepatic cholangiocarcinomas, are often diagnosed late with poor prognosis. A better understanding of cancer initiation could provide potential preventive therapies and increase survival. Models for studying human liver cancer initiation are largely missing. Here, using directly reprogrammed human hepatocytes (hiHeps) and inactivation of p53 and RB, we established organoids possessing liver architecture and function. HiHep organoids were genetically engineered to model the initial alterations in human liver cancers. Bona fide hepatocellular carcinomas were developed by overexpressing c-Myc. Excessive mitochondrion-endoplasmic reticulum coupling induced by c-Myc facilitated hepatocellular carcinoma initiation and seemed to be a target of preventive treatment. Furthermore, through the analysis of human intra-hepatic cholangiocarcinoma-enriched mutations, we demonstrate that the RAS-induced lineage conversion from hepatocytes to intra-hepatic cholangiocarcinoma cells can be prevented by the combined inhibition of Notch and JAK-STAT. Together, hiHep organoids represent a system that can be genetically manipulated to model cancer initiation and identify potential preventive therapies.
Assuntos

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Organoides / Hepatócitos / Fígado / Neoplasias Hepáticas Limite: Animals / Humans Idioma: En Revista: Nat Cell Biol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido

Texto completo: 1 Coleções: 01-internacional Base de dados: MEDLINE Assunto principal: Organoides / Hepatócitos / Fígado / Neoplasias Hepáticas Limite: Animals / Humans Idioma: En Revista: Nat Cell Biol Ano de publicação: 2019 Tipo de documento: Article País de afiliação: China País de publicação: Reino Unido